NIAID TETRAMER FACILITY

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 国家过敏和传染病研究所（NIAID）支持为研究界提供集中资源的试剂计划和储存库。这些设施通过以合理的成本向合格的研究人员提供可靠的质量保证材料、标本或实验动物来源来支持研究。NIAID四聚体设施于1998年在埃默里大学建立，由John Altman博士指导，服务于 作为基础、临床前和临床研究的质量受控四聚体试剂的集中来源，NIAID艾滋病司负责监督该设施，该设施由艾滋病研究和参考试剂计划承包，分包给McKesson BioServices和Virginia Mason。 该设施已向美国和国外非营利组织的研究人员提供了四聚体试剂，包括人，鼠和非人灵长类动物MHC等位基因，包括由十个NIH研究所，食品和药物管理局，国防部，疾病控制和预防中心和私人非营利美国基金会支持的研究人员，以及欧洲，澳大利亚，以色列和加拿大;已生产出适用于广泛T细胞研究的四聚体，包括艾滋病和其他传染病、癌症、器官移植、自身免疫、临床疫苗评估以及T细胞和免疫应答的基础研究;并开发了四聚体使用的标准化方法，并评估了四聚体设计和生产的新进展，以确保该设施的试剂反映最先进的能力

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The National Institute of Allergy and Infectious Diseases (NIAID) supports reagent programs and repositories that provide centralized resources for the research community. These facilities support research by providing reliable sources of quality assured materials, specimens, or experimental animals at reasonable cost to qualified investigators. The NIAID Tetramer Facility, established at Emory University in 1998 under the direction of John Altman, Ph.D., serves the scientific community as a centralized source of quality-controlled tetramer reagents for basic, preclinical, and clinical research. The NIAID Division of AIDS oversees the Facility, which is contracted by the AIDS Research and Reference Reagent Program with subcontracts to McKesson BioServices and Virginia Mason. The Facility has provided tetramer reagents, comprising human, murine, and non-human primate MHC alleles to researchers at non-profit organizations both in the U.S. and abroad, including investigators supported by ten NIH Institutes, the Food and Drug Administration, the Department of Defense, the Centers for Disease Control and Prevention, and private non-profit U.S. foundations, as well as to researchers in Europe, Australia, Israel, and Canada; has produced tetramers applicable to a wide range of T cell studies, including research on AIDS and other infectious diseases, cancer, organ transplantation, autoimmunity, clinical vaccine evaluation, and basic studies on T cells and immune responses; and has developed standardized methodology for tetramer usage and evaluated new advances in tetramer design and production to assure that the Facility's reagents reflect state-of-the-art capabilities.